Navidea Biopharmaceutica (Israel) Performance

NAVB -- Israel Stock  

ILS 95.00  0.40  0.42%

Navidea Biopharmaceutica holds performance score of 21 on a scale of zero to a hundred. The company secures Beta (Market Risk) of 0.5778 which conveys that as returns on market increase, Navidea Biopharmaceutica returns are expected to increase less than the market. However during bear market, the loss on holding Navidea Biopharmaceutica will be expected to be smaller as well.. Although it is essential to pay attention to Navidea Biopharmaceutica price patterns, it is also good to be reasonable about what you can actually do with equity historical price patterns. Macroaxis philosophy towards estimating future performance of any stock is to look not only at its past charts but also at the business as a whole, including all fundamental and technical indicators. To evaluate if Navidea Biopharmaceutica expected return of 1.5418 will be sustainable into the future, we have found twenty-one different technical indicators which can help you to check if the expected returns are sustainable. Use Navidea Biopharmaceutica Treynor Ratio, Value At Risk, Downside Variance, as well as the relationship between Maximum Drawdown and Potential Upside to analyze future returns on Navidea Biopharmaceutica.
Horizon     30 Days    Login   to change

Navidea Biopharmaceutica Relative Risk vs. Return Landscape

If you would invest  8,470  in Navidea Biopharmaceuticals on September 18, 2018 and sell it today you would earn a total of  1,030  from holding Navidea Biopharmaceuticals or generate 12.16% return on investment over 30 days. Navidea Biopharmaceuticals is generating 1.5418% of daily returns and assumes 4.8048% volatility on return distribution over the 30 days horizon. Simply put, 43% of equities are less volatile than Navidea Biopharmaceuticals and 71% of equity instruments are likely to generate higher returns than the company over the next 30 trading days.
 Daily Expected Return (%) 
      Risk (%) 
Assuming 30 trading days horizon, Navidea Biopharmaceuticals is expected to generate 4.5 times more return on investment than the market. However, the company is 4.5 times more volatile than its market benchmark. It trades about 0.32 of its potential returns per unit of risk. The DOW is currently generating roughly -0.08 per unit of risk.

Navidea Biopharmaceutica Market Risk Analysis

Sharpe Ratio = 0.3209
Good Returns
Average ReturnsNAVB
Small Returns
Negative Returns

Navidea Biopharmaceutica Relative Performance Indicators

Estimated Market Risk
  actual daily
 57 %
of total potential
Expected Return
  actual daily
 29 %
of total potential
Risk-Adjusted Return
  actual daily
 21 %
of total potential
Based on monthly moving average Navidea Biopharmaceutica is performing at about 21% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Navidea Biopharmaceutica by adding it to a well-diversified portfolio.

Navidea Biopharmaceutica Performance Rating

Navidea Biopharmaceuticals Risk Adjusted Performance Analysis


Risk-Adjusted Performance

Compared to the overall equity markets, risk-adjusted returns on investments in Navidea Biopharmaceuticals are ranked lower than 21 (%) of all global equities and portfolios over the last 30 days.

Navidea Biopharmaceutica Alerts

Equity Alerts and Improvement Suggestions

Navidea Biopharmaceutica is not yet fully synchronised with the market data
Navidea Biopharmaceutica appears to be very risky and stock price may revert if volatility continues
The company reported revenue of 1.51 M. Net Loss for the year was (17.6 M) with profit before overhead, payroll, taxes, and interest of 1.81 M.
NAVIDEA BIOPHAR has accumulated about 2.21 M in cash with (10.83 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01.
Please see also Stocks Correlation. Please also try Price Ceiling Movement module to calculate and plot price ceiling movement for different equity instruments.